TERAVOLT: Thoracic Cancers International COVID-19 Collaboration

J.G. Whisenant, A. Trama, V. Torri, A. De Toma, G. Viscardi, A. Cortellini, O. Michielin, F. Barlesi, A.M.C. Dingemans, J. Van Meerbeeck, V. Pancaldi, R.A. Soo, N.B. Leighl, S. Peters, H. Wakelee, M.C. Garassino*, L. Horn*

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review


Prior publications on small subsets of cancer patients infected with SARS CoV-2 have shown an increased risk of mortality compared to the general population. Furthermore, patients with thoracic malignancies are thought to be at particularly high risk given their older age, smoking habits, and pre-existing cardio-pulmonary comorbidities. For this reason, physicians around the world have formed TERAVOLT, a global consortium dedicated to understanding the impact of COVID-19 on patients with thoracic malignancies.
Original languageEnglish
Pages (from-to)742-745
Number of pages4
JournalCancer Cell
Issue number6
Publication statusPublished - 8 Jun 2020

Cite this